BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28255095)

  • 1. Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study.
    Freeman M; Offman J; Walter FM; Sasieni P; Smith SG
    BMJ Open; 2017 Mar; 7(3):e013901. PubMed ID: 28255095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
    Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
    Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.
    Offman J; Muldrew B; O'Donovan M; Debiram-Beecham I; Pesola F; Kaimi I; Smith SG; Wilson A; Khan Z; Lao-Sirieix P; Aigret B; Walter FM; Rubin G; Morris S; Jackson C; Sasieni P; Fitzgerald RC;
    BMC Cancer; 2018 Aug; 18(1):784. PubMed ID: 30075763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
    Heberle CR; Omidvari AH; Ali A; Kroep S; Kong CY; Inadomi JM; Rubenstein JH; Tramontano AC; Dowling EC; Hazelton WD; Luebeck EG; Lansdorp-Vogelaar I; Hur C
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1397-1404.e7. PubMed ID: 28238953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.
    Maroni R; Barnes J; Offman J; Scheibl F; Smith SG; Debiram-Beecham I; Waller J; Sasieni P; Fitzgerald RC; Rubin G; ; Walter FM
    BMJ Open; 2022 Apr; 12(4):e054258. PubMed ID: 35393308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
    Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
    Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens.
    Chettouh H; Mowforth O; Galeano-Dalmau N; Bezawada N; Ross-Innes C; MacRae S; Debiram-Beecham I; O'Donovan M; Fitzgerald RC
    Gut; 2018 Nov; 67(11):1942-1949. PubMed ID: 29084829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease?
    Stoltey J; Reeba H; Ullah N; Sabhaie P; Gerson L
    Aliment Pharmacol Ther; 2007 Jan; 25(1):83-91. PubMed ID: 17229223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients.
    Januszewicz W; Tan WK; Lehovsky K; Debiram-Beecham I; Nuckcheddy T; Moist S; Kadri S; di Pietro M; Boussioutas A; Shaheen NJ; Katzka DA; Dellon ES; Fitzgerald RC;
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):647-656.e1. PubMed ID: 30099104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study.
    Kadri SR; Lao-Sirieix P; O'Donovan M; Debiram I; Das M; Blazeby JM; Emery J; Boussioutas A; Morris H; Walter FM; Pharoah P; Hardwick RH; Fitzgerald RC
    BMJ; 2010 Sep; 341():c4372. PubMed ID: 20833740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study.
    Ross-Innes CS; Debiram-Beecham I; O'Donovan M; Walker E; Varghese S; Lao-Sirieix P; Lovat L; Griffin M; Ragunath K; Haidry R; Sami SS; Kaye P; Novelli M; Disep B; Ostler R; Aigret B; North BV; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Sasieni PD; Fitzgerald RC;
    PLoS Med; 2015 Jan; 12(1):e1001780. PubMed ID: 25634542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial.
    Ghimire B; Landy R; Maroni R; Smith SG; Debiram-Beecham I; Sasieni PD; Fitzgerald RC; Rubin G; Walter FM; Waller J; ; Offman J
    BMC Gastroenterol; 2023 Jan; 23(1):7. PubMed ID: 36627580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age- and sex-specific yield of Barrett's esophagus by endoscopy indication.
    Rubenstein JH; Mattek N; Eisen G
    Gastrointest Endosc; 2010 Jan; 71(1):21-7. PubMed ID: 19748616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults.
    Chak A; Lee T; Kinnard MF; Brock W; Faulx A; Willis J; Cooper GS; Sivak MV; Goddard KA
    Gut; 2002 Sep; 51(3):323-8. PubMed ID: 12171951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.
    Solaymani-Dodaran M; Logan RF; West J; Card T; Coupland C
    Gut; 2004 Aug; 53(8):1070-4. PubMed ID: 15247170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oesophageal diseases: gastroesophageal reflux disease, Barrett's disease, achalasia and eosinophilic oesophagitis].
    Calvet X
    Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():49-55. PubMed ID: 26520196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptability to patients of screening disposable transnasal endoscopy: qualitative interview analysis.
    McGoran J; Bennett A; Cooper J; De Caestecker J; Lovat LB; Guha N; Ragunath K; Sami SS
    BMJ Open; 2019 Dec; 9(12):e030467. PubMed ID: 31831531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.